Skip to main content
. 2019 Apr 12;12:845–854. doi: 10.2147/IDR.S195144

Figure 2.

Figure 2

Change of serum HBeAg level and proportion of patients with HBeAg sero-response. HBeAg levels in CHB patients in the IFN+TDF group decreased more rapidly during the 48-week treatment (A), we did not observe significant differences in HBeAg serological loss or seroconversion rates between the two groups at weeks 24 and 48 (B and C).

Abbreviations: CHB, chronic hepatitis B; IFN, interferon; TDF, tenofovir.